DNA methyl transferase inhibitor for the treatment of cancer

Focus: 

To validate the efficacy and safety of a novel cancer drug as a precursor to clinical trials

Anticipated Impact: 

Safer and more effective cancer treatments

Abstract: 

A common feature of cancer is inactivation of genes necessary for normal cellular functions such as programmed cell death. One mechanism of inactivation is called methylation. Epigenetics Pharma will extensively test its lead drug and two derivatives to confirm their ability to reverse methylation of genes. Demethylation of normal genes should allow other cancer drugs to be more effective and could be a mode of cancer treatment in itself. Standard toxicity and dosing experiments will be conducted. Positive study data should attract additional private funds to complete the work that will lead to FDA approval for human clinical trials. LSDF funding will be matched at least equally by a venture capital firm.

Collaborating organizations: Cerep, SNBL USA, Southern Research Institute, University of Washington

Cancer Diagnostics, Therapeutics

Grant Update

Principal Investigator:
Richard Daifuku
Grantee Organization:
Epigenetics Pharma
Grant Title:
DNA methyl transferase inhibitor for the treatment of cancer
Grant Cohort and Year:
2015 Matching (05)
Grant Period:
04/01/2015 - 03/31/2018 (Active)
Grant Amount:
$490,700
NUC013 has been demonstrated to be a DNA methyl transferase inhibitor as well as a ribonucleotide reductase inhibitor. NUC013 was shown to be safer and more effective an animal models of human leukemia and colon cancer compared to the approved drug decitabine.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Mercer Island
Everett
Redmond
Seattle

Legislative Districts:
, 11, 34, 36, 37, 38, 43, 46, 48

Health Impacts

Cancer Diagnostics, Therapeutics